SCHEMBL4664465

SCHEMBL4664465

O=C(O)C1CCN(Cc2cccc3ccccc23)C1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.60
ACHE P22303 1/20 0.58
ALDH1A1 P00352 2/20 0.57
S1PR5 Q9H228 1/20 0.55
HDAC1 Q13547 1/20 0.54
HDAC8 Q9BY41 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
FAAH O00519 1/20 0.52
SIGMAR1 Q99720 3/20 0.52
PDCD1LG2 Q9BQ51 2/20 0.49
CD274 Q9NZQ7 2/20 0.49
DRD4 P21917 2/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
HTR2B P41595 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KDM4E B2RXH2 1/20 0.46
TMEM97 Q5BJF2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5110651 1.00 TSHR (0.60) TSHRACHEALDH1A1S1PR5HDAC1
SCHEMBL8207838 0.92 ACHE (0.65) TSHRACHEALDH1A1S1PR5HDAC1
SCHEMBL8228028 0.88 TSHR (0.59) TSHRACHEHDAC1HDAC8HDAC6
SCHEMBL4662897 0.82 KDM4E (0.54) TSHRALDH1A1SIGMAR1PDCD1LG2CD274
SCHEMBL5107192 0.82 KDM4E (0.54) TSHRALDH1A1SIGMAR1PDCD1LG2CD274
SCHEMBL2160181 0.82 ALDH1A1 (0.61) ALDH1A1S1PR5PDCD1LG2CD274SMN1; SMN2
SCHEMBL4662970 0.82 S1PR5 (0.53) ALDH1A1S1PR5PDCD1LG2CD274
SCHEMBL4769598 0.82 S1PR5 (0.53) ALDH1A1S1PR5PDCD1LG2CD274
SCHEMBL1893898 0.81 ALDH1A1 (0.60) ALDH1A1S1PR5SIGMAR1MEN1KMT2A
SCHEMBL4724721 0.81 ALDH1A1 (0.85) ALDH1A1S1PR5PDCD1LG2CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007787-A2 HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES Novartis AG (CH) 2008-12-31 EP disclosed
US-20080045530-A1 Organic Compounds and Their Uses BRANDL TRIXI 2008-02-21 US disclosed
WO-2007121124-A2 HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES NOVARTIS AG (CH) 2007-10-25 WO disclosed
WO-2007120595-A2 AMINES FOR THE TREATMENT OF HCV NOVARTIS AG (CH) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045530-A1 Organic Compounds and Their Uses OAT, OTC, AOX1 TSHR 3678/4885ACHE 254/4885ALDH1A1 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.